Introduction We present international consensus recommendations for improving diagnosis,
management and treatment access in multiple sclerosis (MS). Our vision is that these will be …

The aetiology and pathophysiology of complex diseases are driven by the interaction between
genetic and environmental factors. The variability in risk and outcomes in these diseases …

The complexity of multiple sclerosis (MS) treatment means that doctors and decision-makers
need the best available evidence to make the best decisions for patient care. Randomized …

Using the ImmunoChip custom genotyping array, we analyzed 14,498 subjects with multiple
sclerosis and 24,091 healthy controls for 161,311 autosomal variants and identified 135 …

Background No treatment has consistently shown efficacy in slowing disability progression
in patients with secondary progressive multiple sclerosis (SPMS). We assessed the effect of …

Objective To examine whether past high sun exposure is associated with a reduced risk of
multiple sclerosis. Design Population based case-control study. Setting Tasmania, latitudes 41…

This study evaluated the gait and balance performance of two clinically distinct groups of
recently diagnosed and minimally impaired multiple sclerosis (MS) patients (Expanded …

Importance Within 2 decades of onset, 80% of untreated patients with relapsing-remitting
multiple sclerosis (MS) convert to a phase of irreversible disability accrual termed secondary …

Background Adequate 25(OH)D levels are required to prevent adverse effects on bone health.
Population-based data on factors associated with 25(OH)D levels of people with MS have …

A number of studies have been conducted with the onset of secondary progressive multiple
sclerosis as an inclusion criterion or an outcome of interest. However, a standardized …